Aktieanalys

Moberg Pharma: Termination of license agreement - Redeye

Redeye Publicerad: 09 Mar 2023 09:57

Redeye sees no big drama in the termination of the license agreement with Taisho Pharmaceutical in Japan. The company regains full rights to the product in Japan and retains the milestone payments of USD 5m. With a strategic revaluation in Taisho moving away from the dermatology field, it is better to get this termination to get a new partner well ahead of a potential launch. We are not changing our estimates or view of Moberg Pharma. The product’s strength makes us believe that Moberg Pharma will get a partner in Japan that suits the needs of that market in due time. The fact that they can retain the milestone payment is a clear positive.

Länk till analysen i sin helhet: https://www.redeye.se/research/888495/moberg-pharma-termination-of-license-agreement?utm_source=finwire&utm_medium=RSS

Nyheter om Moberg Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!